Medpace Holdings, Inc. MEDP Operating Lease Liability Payments - 2024 (Lessee)

Operating Lease Liability Payments - 2024 (Lessee) at other companies

Veeva SystemsVEEV

——

BridgeBio PharmaBBIO

——

Guardant HealthGH

——

West Pharmaceutical ServicesWST

——

Royalty PharmaRPRX

——

Neurocrine BiosciencesNBIX

——

Other financials

Income statement

See full

Revenue$706.6M+26.5%

Operating income$141.5M+24.6%

Net income$123.9M+8.1%

EPS (diluted)$4.28+16.6%

Balance sheet

See full

Cash & equivalents$652.7M+47.9%

Total debt$146.1M-2.8%

Total equity$598.3M+0.8%

Total assets$2.1B+12.2%

Cash flow

See full

Operating cash flow$151.8M+20.6%

CapEx$6.8M-31.8%

Free cash flow$145.0M+25.1%

Valuation

See full

Market cap$13.14B+46.8%

Enterprise value$12.64B+45.9%

P/E28.6×+7.0×

P/S4.9×+0.8×

Profitability

See full

Operating margin21%-0.1pp

Net margin17.2%-2.1pp

FCF margin26.5%+1.5pp

Returns & leverage

See full

Return on equity77.3%+11.4pp

Debt / equity0.2×0.0×

Current ratio0.8×+0.1×

Where this comes from

Reported directly by Medpace Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.

The official record: Medpace Holdings, Inc.’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Medpace Holdings, Inc.'s operating lease liability payments - 2024 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Medpace Holdings, Inc.'s operating lease liability payments - 2024 (lessee)?: Medpace Holdings, Inc. (MEDP) reported operating lease liability payments - 2024 (lessee) of $20.39M in Q1 2026.
How has Medpace Holdings, Inc.'s operating lease liability payments - 2024 (lessee) changed year-over-year?: Medpace Holdings, Inc.'s operating lease liability payments - 2024 (lessee) decreased by 18.2% year-over-year, from $24.94M to $20.39M.